Clinical study with birch pollen hypoallergen DM-101 continues
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt.
In early 2020, Desentum initiated a clinical study to evaluate the safety and tolerability of DM-101, a hypoallergen designed for treating birch pollen allergy. The study was temporarily halted in the spring when the Finnish government issued a state of emergency due to the Covid-19 pandemic. The break was extended over the pollen season, during which Desentum optimized the study protocol based on the information gathered before the halt, and gained regulatory permissions for the continuation of the study.
The recruitment for the study is in progress. The study is conducted in a single study center in Turku, Finland.